InMed Pharmaceuticals Inc. · NASDAQ:INM
InMed Pharmaceuticals — Investor Presentation (November 2023)
29 slides from InMed Pharmaceuticals's investor presentation, November 2023
Slide 1: Corporate Presentation
Corporate Presentation November 2023 :INM www.inmedpharma.com
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements and forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”) including, among others, statements concerning: anticipated development activities, timelines
Slide 3: Overview & Investment Highlights
Overview & Investment Highlights A HYBRID PHARMA R&D COMPANY SUPPORTED BY REVENUE GENERATION • Robust R&D pipeline with 4 candidates in dermatology, ocular and Alzheimer’s • Differentiated approach to the treatment of Alzheimer's • A successful Phase 2 dermatology program currently seeking partnersh
Slide 4: A Rare Cannabinoid Company
A Rare Cannabinoid Company RARE CANNABINOID EXPERTISE ACROSS SEVERAL AREAS Drug Discovery Pharmaceutical R&D Manufacturing Commercial • Pipeline of • Screening of therapeutic • Chemical and • B2B supplier to health pharmaceutical programs candidates biosynthesis expertise and wellness industry • Ski
Slide 5: Cannabinoid Drug Development Programs
Cannabinoid Drug Development Programs
Slide 6: Pharmaceutical Development of Rare Cannabinoids
Pharmaceutical Development of Rare Cannabinoids HIGHLIGHTS SCREENING PRECLINICAL PH 1 PH 2 PH 3 NATURALLY-OCCURRING CANNABINOIDS • Phase 2 - Study completed INM-755 CBN • Showed a positive indication of enhanced anti-itch activity versus control cream Seeking Strategic Partnerships Epidermolysis bul
Slide 7: Phase 2 Clinical Trial: INM-755 Cannabinol (CBN) Cream
Phase 2 Clinical Trial: INM-755 Cannabinol (CBN) Cream Purpose of Trial Patient Enrollment Evaluate the safety of INM-755 CBN cream and obtain preliminary evidence of efficacy in treating symptoms and • Trial enrolled 19 patients wound healing in patients with EB. • 18 remaining patients whose data
Slide 8: Phase 2 Results: INM-755 Cannabinol (CBN) Cream
Phase 2 Results: INM-755 Cannabinol (CBN) Cream Key Results: Non-Wound Itch: Data breakdown Of the 18 participants assessed, chronic itch improved by a • A positive indication of enhanced anti-itch activity clinically meaningful amount in 12 patients (66.7%), of whom: for INM-755 cream versus the co
Slide 9: Glaucoma – A Leading Cause of Blindness for Age 60+
Glaucoma – A Leading Cause of Blindness for Age 60+ CURRENT MEDICATIONS WORK TO REDUCE INTRAOCULAR PRESSURE Unmet medical need Glaucoma market Current treatments do not proactively protect the eye or reverse the progression of glaucoma and only slow the progression of Second leading cause of blindne
Slide 10: INM-088: Potential Roles for CBN in Glaucoma
INM-088: Potential Roles for CBN in Glaucoma CANNABINOL DEMONSTRATES REDUCTION OF IOP AND NEUROPROTECTIVE EFFECTS Front of eye Back of eye IOP reduction Neuroprotection Target Effects of CBN Retina • Direct neuroprotection for the retina and optic nerve, independent of intraocular Pressure pressure
Slide 11: Age-related Macular Degeneration
Age-related Macular Degeneration CBN ANALOG DEMONSTRATED PROMISING EFFECTS RELATED TO THE TREATMENT OF AMD Unmet medical need AMD causes damage to the retina at the back of eye. Currently, AMD market there are no approved treatments for people with dry age-related macular degeneration, which account
Slide 12: INM-089: Increases Thickness of Retina in Preclinical AMD Model
INM-089: Increases Thickness of Retina in Preclinical AMD Model CANNABINOL ANALOG IMPROVES RETINAL FUNCTION INM-089 Preclinical Retina AMD Study Why cannabinoids for ocular disease? • Preserved retinal function in an in vivo Damaged Scientific research is pointing AMD disease model macula at the to
Slide 13: Alzheimer’s Disease – Unmet Medical Need is High
Alzheimer’s Disease – Unmet Medical Need is High CANNABINOIDS MAY OFFER A NEW MULTIPRONGED APPROACH Unmet medical need Medications to treat Alzheimer’s target individual disease components Milestones and may slow the rate of cognitive decline but none have been shown to reverse its effects associate
Slide 14: Alzheimer’s Disease – Advanced Drug Candidates
Alzheimer’s Disease – Advanced Drug Candidates ANTI-AMYLOID BETA AND ANTI-TAU TREATMENT CANDIDATES BEING EXPLORED, FACING CHALLENGES STATUS MECHANISM OF ACTION CHALLENGES Large molecule/biologic Aducanumab (Aduhelm™) Approved Anti-amyloid beta, target both Brain swelling, 35% of patients treated vs
Slide 15: INM-901 demonstrates promising effects in Alzheimer’s preclinical studies
INM-901 demonstrates promising effects in validated Alzheimer’s disease preclinical studies POTENTIAL TO TARGET SEVERAL BIOLOGICAL PATHWAYS ASSOCIATED WITH ALZHEIMER’S DISEASE ALZ Behavioral Studies Neuroprotection Neuritogenesis studies studies • Basal and locomotor activity • Anxiety-related behav
Slide 16: What makes rare cannabinoids potential therapeutic candidates?
What makes rare cannabinoids potential therapeutic candidates? Endocannabinoid Blood-brain Scientific System Barrier Evidence Cannabinoids interact with Cannabinoids are highly lipophilic Mounting research continues the endocannabinoid system and can safely cross the blood brain to demonstrate scien
Slide 17: A Diverse Patent Portfolio
A Diverse Patent Portfolio 13 PATENT FAMILIES – NCEs/Formulations, Manufacturing Methods, Methods of Use NCEs Manufacturing Methods of use 2 patent families filed 7 patent families filed 4 patent families filed • 21 international pending • 2 granted • 2 granted • 29 international pending • 22 intern
Slide 18: Cannabinoids Can Act on Multiple Receptors Expressed in the Brain
Cannabinoids Can Act on Multiple Receptors Expressed in the Brain Examples of receptors expressed in the brain CB1 Receptors concentrated in the brain and central nervous system but are also present in some nerves and organs GPR6 Receptors mainly expressed in the brain, particularly in the striatum.
Slide 19: Why analogs? The potential to enhance natural cannabinoids
Why analogs? The potential to enhance natural cannabinoids UTILIZING EXPERTISE IN DRUG DESIGN TO DEVELOP IMPROVED CANNABINOIDS WITH FAVORABLE PROFILES Target Improved Improve Enhance Patentable Physiological Safety Drug Delivery new chemical Outcomes Profile Formulation entity • Design cannabinoid •
Slide 20: BayMedica Commercial Business
BayMedica Commercial Business
Slide 21: BayMedica - Wholesale Rare Cannabinoids for the H&W Market
BayMedica -Wholesale Rare Cannabinoids for the H&W Market HIGH PURITY, CONSISTENT & BIOIDENTICAL TO NATURE CBC CBDV THCV CBT Cannabichromene Cannabidivarin Tetrahydrocannabivarin Cannabicitran CONSISTENCY C O S T- E F F E C T I V E N E S S High quality, bioidentical rare cannabinoids with exceptiona
Slide 22: BayMedica – Revenue Trending Positively
BayMedica – Revenue Trending Positively INCREASED DEMAND FOR BAYMEDICA’S BIOIDENTICAL RARE CANNABINOIDS 12 Month Trailing Sales US$ (000’s) Fiscal 2023 Revenue Growth US$ (000’s) $2.3M 2,500 +123% 5,000 4,500 2,000 4,000 3,500 1,500 3,000 $1.03M $895K 2,500 +120% -61% 1,000 $470K 2,000 1,500 $320K +
Slide 23: Rare Cannabinoids in Health and Wellness – Rapidly Emerging Sector
Rare Cannabinoids in Health and Wellness – Rapidly Emerging Sector CBC GROWTH TREND - SIMILAR TO OTHER MORE ESTABLISHED RARE CANNABINOIDS Sales of products containing rare Total Infused Gummies Sales in US cannabinoids – significant increase over the (Sales % Change: 4Q22 vs. 4Q21) last 3 years CBG
Slide 24: Corporate
Corporate
Slide 25: Bringing Together a Depth of Cannabinoid Expertise
Bringing Together a Depth of Cannabinoid Expertise EXTENSIVE EXPERIENCE IN PHARMA R&D, CANNABINOID/API MANUFACTURING, CLINICAL AND REGULATORY Eric A. Adams, MIBS Michael Woudenberg, PEng Alexandra Mancini, MSc Eric Hsu, PhD Colin Clancy Chief Executive Officer Chief Operating Officer SVP, Clinical &
Slide 26: Seasoned Board of Directors
Seasoned Board of Directors Andy Hull Janet Grove, QC Bryan Baldasare, Nicole Lemerond, CFA Eric A. Adams, MIBS Chair of Board of Directors Chair, Governance and Chair, Audit Committee Chair, Compensation Chief Executive Officer Nominations Committee Committee Andy Hull has over 30 years of Mr. Adam
Slide 27: Financial Snapshot
Financial Snapshot As of 2023-11-17 Cash and Short-term Investments $11.4 M(1) Shares I/O 9.6 M(2) Options 0.1 M Warrants and Preferred Investment Options (9.6M @$0.83 cents) 10.2 M Fully Diluted Shares 19.9 M Close US$0.45 52-week High US$4.75 52-week Low US$0.36 Avg. Daily Volume (Trailing 50 Days
Slide 28: Fiscal 2024 – Key Value Drivers
Fiscal 2024 – Key Value Drivers • Advance INM-901 in preclinical in vivo studies and CMC preparation • Advance ocular program towards human clinical trials in 2025 • Evaluate commercial partnerships for INM-755 • Target proprietary cannabinoid analogs for pharma R&D pipeline • Supporting BayMedica r
Slide 29: Thank you!
UNLOCKING THE POTENTIAL OF CANNABINOID MEDICINES Thank you! Colin Clancy Vice President, Investor Relations & Corporate Communications [email protected] +1-604-416-0999 :INM www.inmedpharma.com
InMed Pharmaceuticals — Investor Presentation (November 2023) on 6ix